You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDihydromorphine
Accession NumberDB01565
TypeSmall Molecule
GroupsExperimental, Illicit
DescriptionA semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem]
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIC3S5FRP6JW
CAS number509-60-4
WeightAverage: 287.3535
Monoisotopic: 287.152143543
Chemical FormulaC17H21NO3
InChI KeyInChIKey=IJVCSMSMFSCRME-KBQPJGBKSA-N
InChI
InChI=1S/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-triene-10,14-diol
SMILES
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC[C@@H]2O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationDihydromorphine is an opioid analgesic used for moderate to severe pain relief.
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Dihydromorphine Action PathwayDrug actionSMP00689
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.985
Caco-2 permeable+0.8356
P-glycoprotein substrateSubstrate0.8896
P-glycoprotein inhibitor INon-inhibitor0.8653
P-glycoprotein inhibitor IINon-inhibitor0.9868
Renal organic cation transporterInhibitor0.5516
CYP450 2C9 substrateNon-substrate0.8115
CYP450 2D6 substrateSubstrate0.8647
CYP450 3A4 substrateSubstrate0.7582
CYP450 1A2 substrateNon-inhibitor0.797
CYP450 2C9 inhibitorNon-inhibitor0.9309
CYP450 2D6 inhibitorNon-inhibitor0.617
CYP450 2C19 inhibitorNon-inhibitor0.7678
CYP450 3A4 inhibitorNon-inhibitor0.8793
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9646
Ames testNon AMES toxic0.7901
CarcinogenicityNon-carcinogens0.9598
BiodegradationNot ready biodegradable0.9846
Rat acute toxicity2.8928 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8927
hERG inhibition (predictor II)Non-inhibitor0.8414
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point157 dec °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility1.82 mg/mLALOGPS
logP1.26ALOGPS
logP1.08ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)10.29ChemAxon
pKa (Strongest Basic)9.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area52.93 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.16 m3·mol-1ChemAxon
Polarizability30.66 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Herbert Merz, Ingrid Wiedemann, Helmut Ensinger, Klaus Stockhaus, Matthias Grauert, “14-hydroxy-N-(2-methoxyethyl)-7,8-dihydromorphine and -norisomorphine, processes for the preparation thereof and the use thereof as pharmaceutical compositions.” U.S. Patent US5240933, issued August 31, 1993.

US5240933
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydromorphine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Dihydromorphine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with 7-Nitroindazole.
AcepromazineAcepromazine may increase the hypotensive activities of Dihydromorphine.
AcepromazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydromorphine.
adipiplonThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dihydromorphine.
AlimemazineAlimemazine may increase the hypotensive activities of Dihydromorphine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Dihydromorphine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydromorphine.
AlvimopanThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amiloride.
AmisulprideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Dihydromorphine which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydromorphine.
AmoxapineDihydromorphine may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dihydromorphine.
AmperozideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Dihydromorphine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dihydromorphine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydromorphine.
ArticaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Asenapine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydromorphine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dihydromorphine.
AzaperoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Azaperone.
AzelastineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dihydromorphine.
AzosemideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dihydromorphine.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dihydromorphine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dihydromorphine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dihydromorphine.
BenzphetamineBenzphetamine may increase the analgesic activities of Dihydromorphine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Benzyl alcohol.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydromorphine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.
BrimonidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dihydromorphine.
BrompheniramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydromorphine.
BuprenorphineBuprenorphine may decrease the analgesic activities of Dihydromorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydromorphine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydromorphine.
ButacaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dihydromorphine.
ButorphanolButorphanol may decrease the analgesic activities of Dihydromorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dihydromorphine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Dihydromorphine.
CarisoprodolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dihydromorphine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dihydromorphine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dihydromorphine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dihydromorphine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydromorphine.
ChlorphentermineChlorphentermine may increase the analgesic activities of Dihydromorphine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Dihydromorphine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydromorphine.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dihydromorphine.
CitalopramDihydromorphine may increase the serotonergic activities of Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with clomethiazole.
ClomipramineDihydromorphine may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dihydromorphine.
ClonazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydromorphine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dihydromorphine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dihydromorphine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydromorphine.
ConivaptanThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Conivaptan.
CyclizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydromorphine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dihydromorphine.
CyclothiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydromorphine.
DapoxetineDihydromorphine may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydromorphine.
deramciclaneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydromorphine.
DesipramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dihydromorphine.
DesmopressinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dihydromorphine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydromorphine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Dihydromorphine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dihydromorphine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydromorphine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dihydromorphine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dihydromorphine.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydromorphine.
DifenoxinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dihydromorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihydromorphine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydromorphine.
DoramectinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.
DoxylamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Dihydromorphine.
DrospirenoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dihydromorphine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydromorphine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dihydromorphine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Efonidipine.
EluxadolineDihydromorphine may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dihydromorphine.
EntacaponeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Entacapone.
EplerenoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Eplerenone.
EscitalopramDihydromorphine may increase the serotonergic activities of Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dihydromorphine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydromorphine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etacrynic acid.
EthanolDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Dihydromorphine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydromorphine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dihydromorphine.
EthosuximideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dihydromorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dihydromorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydromorphine.
EtoperidoneDihydromorphine may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dihydromorphine.
EzogabineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dihydromorphine.
FenfluramineDihydromorphine may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydromorphine.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydromorphine.
FexofenadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dihydromorphine.
FluoxetineDihydromorphine may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydromorphine.
FluphenazineFluphenazine may increase the hypotensive activities of Dihydromorphine.
FluphenazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydromorphine.
FluspirileneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluticasone Propionate.
FluvoxamineDihydromorphine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dihydromorphine.
FosphenytoinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydromorphine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dihydromorphine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dihydromorphine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dihydromorphine.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Dihydromorphine.
GuanfacineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dihydromorphine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dihydromorphine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dihydromorphine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Dihydromorphine.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dihydromorphine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydromorphine.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydromorphine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dihydromorphine.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydromorphine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Dihydromorphine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.
HydroxyzineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dihydromorphine.
IloperidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Imipramine.
IndalpineDihydromorphine may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Indapamide.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydromorphine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dihydromorphine.
IsosorbideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Isosorbide.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydromorphine.
KetazolamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ketobemidone.
KW-3902The risk or severity of adverse effects can be increased when Dihydromorphine is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dihydromorphine.
LevocabastineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dihydromorphine.
LevomilnacipranDihydromorphine may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydromorphine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dihydromorphine.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Dihydromorphine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydromorphine.
LofentanilThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dihydromorphine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydromorphine.
Lu AA21004Dihydromorphine may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Dihydromorphine.
LurasidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydromorphine.
MeclizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dihydromorphine.
MelperoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Dihydromorphine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydromorphine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydromorphine.
MersalylThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Dihydromorphine.
MesoridazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dihydromorphine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dihydromorphine.
MethamphetamineMethamphetamine may increase the analgesic activities of Dihydromorphine.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dihydromorphine.
MethapyrileneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydromorphine.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Dihydromorphine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydromorphine.
MethsuximideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Dihydromorphine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydromorphine.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Dihydromorphine.
MetolazoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metolazone.
MetyrosineDihydromorphine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydromorphine.
MilnacipranDihydromorphine may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.
MirtazapineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dihydromorphine.
MolindoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Dihydromorphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydromorphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Dihydromorphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.
NabiloneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nabilone.
NalbuphineNalbuphine may decrease the analgesic activities of Dihydromorphine.
NalbuphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Dihydromorphine can be decreased when used in combination with Naltrexone.
NitrazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Dihydromorphine.
OlanzapineDihydromorphine may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydromorphine.
OlopatadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydromorphine.
OpiumThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Opium.
OrphenadrineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dihydromorphine.
OsanetantThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydromorphine.
OxprenololThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dihydromorphine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydromorphine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydromorphine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydromorphine.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dihydromorphine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydromorphine.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydromorphine.
ParaldehydeDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Dihydromorphine.
ParoxetineDihydromorphine may increase the serotonergic activities of Paroxetine.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydromorphine.
PentazocinePentazocine may decrease the analgesic activities of Dihydromorphine.
PentazocineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydromorphine.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dihydromorphine.
PerampanelThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Dihydromorphine.
PerphenazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydromorphine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydromorphine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Dihydromorphine.
PhenytoinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydromorphine.
PipamperoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydromorphine.
PipotiazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydromorphine.
PiretanideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pomalidomide.
PotassiumThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium Citrate.
PramipexoleDihydromorphine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dihydromorphine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dihydromorphine.
PrimidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dihydromorphine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Dihydromorphine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dihydromorphine.
PromazinePromazine may increase the hypotensive activities of Dihydromorphine.
PromazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Dihydromorphine.
PromethazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dihydromorphine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dihydromorphine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydromorphine.
PropoxycaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Dihydromorphine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydromorphine.
QuinethazoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dihydromorphine.
RamelteonThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ramelteon.
RamosetronDihydromorphine may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydromorphine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydromorphine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydromorphine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydromorphine.
RomifidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Romifidine.
RopiniroleDihydromorphine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydromorphine.
RotigotineDihydromorphine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dihydromorphine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydromorphine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydromorphine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydromorphine.
SertindoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Sertindole.
SertralineDihydromorphine may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydromorphine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dihydromorphine.
SpironolactoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Dihydromorphine.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydromorphine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydromorphine.
SuvorexantThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydromorphine.
TetrabenazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetrodotoxin.
ThalidomideDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dihydromorphine.
TheobromineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydromorphine.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Dihydromorphine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dihydromorphine.
ThioridazineThioridazine may increase the hypotensive activities of Dihydromorphine.
ThioridazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tiagabine.
TicrynafenThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Dihydromorphine.
TizanidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydromorphine.
TolvaptanThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydromorphine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dihydromorphine.
TrazodoneDihydromorphine may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydromorphine.
TriamtereneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydromorphine.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Dihydromorphine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Dihydromorphine.
TriflupromazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dihydromorphine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydromorphine.
TrimipramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dihydromorphine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dihydromorphine.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydromorphine.
UlaritideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Dihydromorphine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dihydromorphine.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydromorphine.
VigabatrinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Vigabatrin.
VilazodoneDihydromorphine may increase the serotonergic activities of Vilazodone.
VortioxetineDihydromorphine may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dihydromorphine.
XylazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydromorphine.
ZiconotideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ziconotide.
ZimelidineDihydromorphine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydromorphine.
ZolazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dihydromorphine.
ZonisamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dihydromorphine.
ZotepineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13. [PubMed:16777416 ]
  2. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215 ]
  3. Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30. [PubMed:15178355 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13. [PubMed:16777416 ]
  2. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215 ]
  3. Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30. [PubMed:15178355 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13. [PubMed:16777416 ]
  2. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215 ]
  3. Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30. [PubMed:15178355 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
E3 ubiquitin ligase involved in the retrotranslocation and turnover of membrane and secretory proteins from the ER through a set of processes named ER-associated degradation (ERAD). This process acts on misfolded proteins as well as in the regulated degradation of correctly folded proteins. Enhances ionizing radiation-induced p53/TP53 stability and apoptosis via ubiquitinating MDM2 and AKT1 and...
Gene Name:
TRIM13
Uniprot ID:
O60858
Molecular Weight:
46987.08 Da
References
  1. Liebmann C, Schnittler M, Hartrodt B, Born I, Neubert K: Structure-activity studies of novel casomorphin analogues: binding profiles towards mu 1-, mu 2- and delta -opioid receptors. Pharmazie. 1991 May;46(5):345-8. [PubMed:1654566 ]
  2. Maneckjee R, Archer S, Zukin RS: Characterization of a polyclonal antibody to the mu opioid receptor. J Neuroimmunol. 1988 Feb;17(3):199-208. [PubMed:2828423 ]
  3. Ishizuka Y, Oka T: Relation of diltiazem binding sites to opioid receptor subtypes in the guinea-pig brain. Tokai J Exp Clin Med. 1987 Mar;12(1):11-7. [PubMed:2835832 ]
  4. Koman A, Kolb VM, Terenius L: A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. Pharm Res. 1987 Apr;4(2):147-9. [PubMed:2855368 ]
  5. Ho CL, Hammonds RG Jr, Li CH: Opiate receptor binding profile in the rabbit cerebellum and brain membranes. Biochem Pharmacol. 1985 Apr 1;34(7):925-31. [PubMed:2985086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Type 4 melanocortin receptor binding
Specific Function:
ACTH stimulates the adrenal glands to release cortisol.MSH (melanocyte-stimulating hormone) increases the pigmentation of skin by increasing melanin production in melanocytes.Beta-endorphin and Met-enkephalin are endogenous opiates.
Gene Name:
POMC
Uniprot ID:
P01189
Molecular Weight:
29423.72 Da
References
  1. Somoza E: Influence of neuroleptics on the binding of met-enkephalin, morphine and dihydromorphine to synaptosome-enriched fractions of rat brain. Neuropharmacology. 1978 Aug;17(8):577-81. [PubMed:29252 ]
  2. Johnson N, Houghten R, Pasternak GW: Binding of 3H-beta-endorphin in rat brain. Life Sci. 1982 Sep 20-27;31(12-13):1381-4. [PubMed:6292632 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:10 / Updated on August 17, 2016 12:23